Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies? Raffaele CalifanoOurania RomanidouFiona Blackhall Current Opinion 29 April 2016 Pages: 831 - 840
Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease S. N. SalamA. KhwajaM. E. Wilkie Therapy in Practice 03 May 2016 Pages: 841 - 852
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma Philippe MoreauNiels W. C. J. van de DonkMaría-Victoria Mateos Therapy in Practice 25 April 2016 Pages: 853 - 867
Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia Celeste B. BurnessGillian M. KeatingKarly P. Garnock-Jones Adis Drug Evaluation 05 May 2016 Pages: 869 - 878
Gabapentin Enacarbil: A Review in Restless Legs Syndrome Esther S. KimEmma D. Deeks Adis Drug Evaluation 04 May 2016 Pages: 879 - 887
Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia Lesley J. Scott Adis Drug Evaluation 18 May 2016 Pages: 889 - 900
Erratum to: Management Strategies for Clopidogrel Hypersensitivity Craig J. BeaversNicolas W. CarrisKathryn M. Ruf Erratum 29 April 2016 Pages: 913 - 913
